Introduction
Arterial thrombotic diseases (i.e. myocardial infarction (MI) and ischemic stroke) and venous thromboembolism (i.e. deep vein thrombosis (DVT) and pulmonary embolism (PE)) have traditionally been considered as separate diseases with distinct etiology and treatment strategies.
However, later studies have suggested a potential link between arterial and venous thrombosis. A higher frequency of carotid plaques has been found in patients with unprovoked VTE compared to patients with provoked VTE and hospitalized controls. 1 Moreover, a study of consecutive autopsies reported an association between atherothrombosis and VTE, 2 and the highest prevalence of previous hospitalization for MI and stroke was found among VTE patients in a case-control study of more than 60 000 VTE patients and population controls. 3 Growing evidence support an association between VTE and future arterial thrombotic events. In studies of patients with VTE, subjects with unprovoked events had higher risk of arterial thrombotic disease than patients with provoked events. [4] [5] [6] [7] However, the risk was assessed in selected cohorts (e.g. patients with a previous history of PE), [4] [5] [6] or included a low number of study participants. 7 A large population-based registry study, with more than 200 000 subjects, reported that patients with VTE had substantially higher long-term incidence of subsequent arterial thrombotic diseases. 8 However, information about potential confounders, such as body mass index (BMI), was not available in this study. 8 In addition, the attributable risk and the population attributable risk of arterial thrombotic disease due to VTE were not reported. Such data are essential, as a considerable proportion of arterial events attributable to VTE could imply a role for long-term treatment to prevent subsequent arterial events in VTE patients.
The aim of this study was to investigate the association between incident VTE and future risk of arterial thromboembolic events in a general population, and adjust for potential case-control study of more than 60 000 VTE patients and population controls. 3 Growing evidence support an association between VTE and future arterial thrombotic ev ven en ents ts ts. In In In s s stu tu tudi d es es s o o of f patients with VTE, subjects s s wi wi wit th unprovoked d d even en nts ts ts had higher risk of ar rte e er rial thrombo boti t t c c c di di is s sea as ase e e th th tha an an p pat at a i ie ien nt ts s with th h p p provo vo vok ked d d e ev eve en nt ts ts. 4-4-7 4-7 H H How owev ev ver er, , th th the e ri ri isk sk sk w wa a as a a ass sse es ess sed n n s s sel el elec ec ecte ted d co co coho hor r rts s s (e (e.g . .g. pa pa p tie en ents ts ts wi wi wit th th a a a p p pre re rev v viou ou us s h h his st stor or ry y of of of P PE) E) E), , 4 4 4-6 o o or r r in in ncl l lud uded ed e a a a l low ow ow num um umbe ber r r of of f tudy particip ip pan an ants ts. . 7 7 7 A A A l lar ar a ge ge e p p pop op opul ul ulat atio io ion-n--ba ba base se sed d d re re regi gi gist st stry ry ry st t tud ud udy, y, y, w w wit it ith h h mo mo more re re t t tha ha han n n 20 20 00 0 0 00 00 000 0 0 su s bjects, confounders such as BMI. We conducted individual-level analyses of two prospective population-based cohorts and assessed the absolute and relative risks of first-time arterial thrombotic disease, including acute MI and ischemic stroke, after a first episode of VTE.
Methods

Study population
Subjects were recruited from the fourth survey of the Tromsø Study (conducted in 1994-95), and from the Diet, Cancer and Health (DCH) Study (conducted in 1993-97). The Tromsø Study and the DCH Study are population-based studies, with repeated health surveys of inhabitants in Tromsø, Norway, and Copenhagen and Aarhus, Denmark, respectively. The study populations have been described in detail elsewhere. 9, 10 In the fourth survey of the Tromsø Study, all inhabitants aged 25 years or older were invited and 27 158 (77% of the eligible population)
participated. In the DCH Study, all inhabitants living in the urban areas of Copenhagen and
Aarhus were invited to participate if they were born in Denmark, between 50 to 65 years of age and did not have a diagnosis of cancer in the Danish Cancer Registry at enrollment, and 57 054 subjects participated.
The study was approved by the regional committees for research ethics in Tromsø, Aarhus and Copenhagen, respectively, and all subjects gave their informed written consent.
Subjects who did not consent to medical research (n= 243) and subjects not officially registered as inhabitants of the municipalities at baseline (n= 44) were excluded from the study.
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Atherosclerotic risk factors
Baseline information was collected by physical examinations and self-administered questionnaires. Height and weight were measured, BMI calculated and blood pressure was recorded, as described elsewhere. 11, 12 Detailed information on diabetes mellitus, hypertension, hypercholesterolemia, smoking, physical activity, education level and medication use including hormone replacement therapy, oral contraceptives, antihypertensives and lipid lowering drugs, was collected from self-administered questionnaires. Non-fasting blood samples were collected and total cholesterol measured as previously described. 11, 12 Obesity was classified based on BMI according to the World Health Organization (WHO) definition. 13 Hypertension was classified as mean systolic blood pressure 140 mmHg, mean diastolic blood pressure 90 mmHg, selfreported use of blood pressure lowering drugs, or self-reported hypertension.
Hypercholesterolemia was classified as total serum cholesterol 6.5 mmol/l, self-reported use of lipid lowering drugs, or self-reported hypercholesterolemia.
Registry of VTE
Only objectively verified symptomatic VTE events were included in the study and the VTE events were similarly validated and recorded in the Tromsø and the DCH Study. All first-time events of VTE during follow-up in the Tromsø Study were identified by searching the hospital discharge diagnosis registry, the autopsy registry, and the radiology procedure registry of the University Hospital of North Norway from date of enrollment (1994-95) to December 31, 2010, as previously described. 14 A VTE event derived from the hospital discharge diagnosis registry or the radiology procedure registry, was verified and recorded when presence of clinical signs and and total cholesterol measured as previously described. Hy Hy ype pe perc rc rcho hole le est st ster ero ol lem em mia ia a w w was as cla la l ss ss sif if ifie ie ied d d a as as t t tot ot ota al al s s ser er e um um m c ch ho hole le lest st ster erol ol ol 6 6 6.5 .5 .5 m m mm mo mol/ l/ /l, l, l, s s sel elf-f-f-re re repo po orte ed ed u u use e e o of ipid lowering ng ng d d dru ru ugs gs gs, , or or or sel el lf-f-f re re r po po port rt r ed ed ed h h hyp yp yper er erch ch chol ol oles es ste te tero ro role emi mi mia. a. a symptoms of DVT or PE were combined with objective confirmatory tests (compression ultrasonography, venography, spiral computed tomography, perfusion-ventilation scan, pulmonary angiography, or autopsy), and resulted in a VTE diagnosis that required treatment.
VTE cases from the autopsy registry were recorded when the death certificate indicated VTE as cause of death or as a significant condition contributing to death.
In the DCH Study, all incident VTE events were identified by linking the cohort with the In both studies, trained personnel reviewed the medical records for each potential VTEcase. Concurrent DVT and PE were registered as PE. Verified events were classified as unprovoked or provoked based on the presence of provoking factors at the time of diagnosis, as previously described in detail. 12, 14 In the last update of VTE events in the DCH Study (July 2006 to April 2008), verified VTEs were not further classified. Therefore, 136 VTE patients had missing information on localization (DVT/PE) and 146 had missing on classification (unprovoked/provoked).
Registry of arterial thrombotic events
In the Tromsø Study, all first-time events of myocardial infarction and ischemic stroke were identified by searching the hospital and out-of hospital medical records, the autopsy registry and the death certificates, as previously described. 11, 15 The national unique 11-digit identification VTE were combined with confirmatory diagnostic test results (ultrasound, venog g gra raph ph p y, y, y, echocardiography, ventilation-perfusion lung scan, or computed tomography scan), or when au uto to ops ps psy y y ve ve eri ri rifi fi f ed d V V VT TE.
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Statistical analyses
Subjects who developed VTE during the study period contributed with non-exposed person-time from the baseline inclusion date to the date of a diagnosis of VTE, and then with exposed persontime from the date of VTE and onwards. For each participant, non-exposed and exposed personyears were counted from the date of enrollment to the date of an incident diagnosis of arterial thrombotic disease (i.e. MI and ischemic stroke), the date the participant died or moved from the were validated by direct review of medical records in accordance with the guidel elin i ines e e o o of f f th th the e e American Heart Association and the European Society of Cardiology for use in epidemiology. Baseline differences between groups were tested by one-way ANOVA for continuous variables, and by chi-square for categorical variables. Crude incidence rates (IR) of arterial thrombotic disease were calculated and expressed as number of events per 1000 personyears at risk. Cox proportional hazard regression models were used to estimate crude and multivariable adjusted hazard ratios (HR) with 95% confidence intervals (CI) for arterial thrombotic disease, MI and ischemic stroke. Age was used as time-scale, with participants' age at study enrollment defined as entry-time, and exit-time defined as age at the censoring event (arterial thrombotic disease, death, migration or study end). The exposure variable (VTE) was included as a time-dependent covariate, i.e. no participants were registered with VTE at baseline, but the variable was updated for those who developed VTE during follow-up. The multivariable HRs were adjusted for age, BMI, diabetes, hypertension, hypercholesterolemia, smoking, physical activity, and education level. In addition, subgroup analyses of PE and DVT as exposure variables for arterial thrombotic disease were performed using the same time-varying approach. Statistical interactions between VTE and age or sex were tested by including crossproduct terms in the proportional hazard model. Further analyses were stratified by sex and age ( 65 years). The proportional hazard assumption was verified by evaluating the parallelism between the curves of the log-log survivor function.
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Downloaded from
In order to show the change in risk of arterial events over time, crude incidence rates of arterial thrombotic disease, MI and ischemic stroke were plotted against time (1, 3, 5, 7 and 10 years) after an episode of VTE, DVT or PE, respectively, using GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA).
Attributable risk (AR%), the proportion of events among the exposed subjects that can be explained by the exposure, was calculated from incidence rates of arterial thrombotic disease in the VTE (I e ) and non-VTE (I 0 ) population (100% * (I e -I 0 ) / I e ). Population attributable risk fraction (PAR%), the proportion of events in the study population attributable to the exposure, was calculated using the incidence rates of arterial thrombotic disease in the general population (I p ) and in the non-VTE (I 0 ) population (100% * (I p -I 0 ) / I p ).
Results
In our population, 1 208 subjects with a first-time VTE event were identified, of which 90 developed a subsequent incident arterial thrombotic event (i.e. MI and ischemic stroke). Baseline characteristics of study participants are shown in Table 1 . Compared to those who developed arterial events only, those who developed an incident arterial thrombotic disease after a VTE event had higher mean age and BMI values, comprised higher proportions of subjects with diabetes, hypertension and hypercholesterolemia, and had a lower proportion of men and subjects who regularly performed exercise.
Characteristics of the VTE events are shown in Re Resu su sult lt lts s s n n o o our u populat tio ion n n, 1 2 2 208 08 8 s s b ub ubje je ject cts s wi wi with th a a first t-t t time e V V VTE E E e e eve ve ent nt t w we e ere e e id id de en nt ti ifi fied ed ed, , of of w w whi hi h ch ch ch 9 9 90 0 0 de dev ve velo lo lope pe ped d a a a su subs bs seue uent nt i inc ncid id den en nt t t ar ar arte t teri rial al t t thr hr hrom om ombo bo b t t tic c c ev v ven en nt t t ( (i (i.e e e. . M MI MI a a and nd n is sc che he emi mi mic c st st stro ro roke e e). B Bas as sel l lin ine characteristic cs s s of of o s s stu tu tudy dy dy p p par r rti ti t ci ci c pa pa ant nt n s s ar a a e e e sh sh show ow own n n in in i Ta Ta Tabl b b e e e 1 1 1. Co Co Comp mp mpar ared ed ed t t to o o th th thos os o e e wh wh who o o de de developed subjects had other medical conditions present at the time of VTE ( Table 2) .
Incidence rates and hazard ratios for arterial thrombotic diseases by VTE and subtypes of VTE are shown in Table 3 ). The incidence rate of arterial events in VTE subjects differed according to VTE type, and changed with time after the VTE episode (Figure 1) . The highest crude incidence rate of arterial thrombotic disease (Figure 1a) , MI (Figure 1b) and ischemic stroke (Figure 1c) was found the first year after a PE event.
A significant statistical interaction was found between VTE and sex, and between VTE and age. When analyses were stratified by sex and the age of 65 years, the association between VTE and subsequent arterial thrombotic disease applied to all women and to men below 65 years of age ( Table 3) . T Th he he a a att tri ri ibu bu buta ta tab bl ble e isk of arterial thrombotic disease among VTE patients was 63.8%, and 0.9% of the arterial ev ven en ents ts ts i i in n th th the e p popu pu pul la lation were attributable to VT TE E E. I I In subgroup ana na n lys ses es es, , PE P , but not DVT, was 
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Discussion
In the present study, incident venous thromboembolism was associated with increased risk of future myocardial infarction and ischemic stroke. Specifically, women of all ages and men below 65 years of age suffering from a VTE event had higher risk of major arterial thrombotic diseases compared with those without VTE. In women, PE and DVT provided similar risk estimates of arterial events, whereas PE rather than DVT appeared to predict arterial thrombotic diseases in men. The incidence rate of arterial events was highest the first year after a PE episode. The population attributable risk of arterial thrombotic disease by incident VTE was only 0.9%, and the VTE event explained 64% of the risk for arterial events in VTE patients.
The mechanism behind the observed association between VTE and arterial thrombotic diseases is not fully understood. Potentially, atherosclerosis may initiate both venous and arterial thrombosis by a similar pro-thrombotic trigger, such as inflammation. 19, 20 Prospective studies of general populations have, however, failed to confirm an association between atherosclerosis and VTE. 21, 22 Moreover, growing evidence support the concept that traditional atherosclerotic risk factors including diabetes, hypertension and dyslipidemia are not associated with venous thrombosis. 11, [23] [24] [25] [26] Obesity and advancing age are shared risk factors for arterial and venous thrombosis. However, adjustments for age and BMI in addition to traditional atherosclerotic risk factors only modestly affected the risk estimates, indicating that these two common factors could not fully explain the observed association between VTE and risk of future MI. Modifiable risk factors such as smoking, diabetes, hypertension and hypercholesterolemia may change over time, and residual confounding by these factors cannot be ruled out. Moreover, unknown confounders may still be present, and could potentially explain the association. In a recently published study, common etiologic factors including genetic thrombophilia and procoagulant markers explained
The mechanism behind the observed association between VTE and arteria ia al th th thro o omb mb mbot ot oti ic ic diseases is not fully understood. Potentially, atherosclerosis may initiate both venous and arterial h hro ro omb mb mbos osis is is b b by y y a a si si sim m milar pro-thrombotic trigger, su su suc ch h as inflamma ati ti t on n. . 1 19, 19, 20 2 2 Prospective studies of g gen ne neral popula ati i tion on ons ha ha have ve e, ho ho howe w weve ve er, r, r, f fa ai ile e ed to o o c c conf f f r irm m an an an a ass ss so oc cia iat t tio on on b b be e etw we ween en n a ath ther er eros os scl cl ler ero os osis s is a a an nd f f f f VT VT TE. E. E. 21, 21, 22 M M Mo or oreo eo ove e er, r, g g gro o owi w ng ng g e evi vi vide de denc nce e e su su supp pp ppor or rt t t th th he e co co onc nc cep ep ept t t th th hat at a tra ra adi di d ti ti ion on nal al a a at the he hero ro osc sc cl ler ro roti ti ic c ri ri isk k k factors includ ud din in ing g g di di diab ab a et et etes e e , , hy hy hype pe ert rt rten en ensi si s on on n a a and nd nd d d dys ys ysli li lipi pi p de de d mi mi mia a a ar ar are e e no no not t t as as asso so oci ci ciat at ated ed ed w w wit it th h h ve ve veno no n us It is also possible that the observed association is not explained by common risk factors, but restricted to the events themselves or treatment thereof. In our study, PE was a stronger predictor than DVT for future MI. Thus, it can be hypothesized that local disturbances in the cardiopulmonary circulation caused by PE may predispose for clotting in the coronary arteries.
In addition, a paradoxical embolism from a venous source through a patent foramen ovale may lead to ischemic stroke and MI. 36, 37 Vascular calcification is associated with increased cardiovascular risk. In animal models, treatment with vitamin K antagonists led to arterial calcification, 38 and long-term use of vitamin K antagonists was associated with extracoronary vascular calcification in humans, even after adjustments for other risk factors. 39 Thus, hypothetically, long-term treatment of VTE with vitamin K antagonists could lead to arterial thrombotic disease through arterial calcification.
VTE was not associated with higher risk of arterial events in elderly men. Although these findings should be interpreted with caution due to limited statistical power in subgroup analyses, it may shed light over differential pathogenesis of arterial thrombotic disease in men and women.
In general, women have lower risk of arterial events and are older at time of diagnosis than men with similar risk profiles. 40 The risk factors associated with arterial events in females are found predictor than DVT for future MI. Thus, it can be hypothesized that local disturba ba anc nc ces s s i i in n n th th the e e cardiopulmonary circulation caused by PE may predispose for clotting in the coronary arteries.
n n a a add dd ddit it iti io ion, n, n, a a par ar rad ad ado oxical embolism from a venou ou ous source through gh gh a p pat at ate en ent foramen ovale may e ead d d to ischem mic ic st t trok ok ke e an an and d d MI MI MI. . 36, 36, 6 37 7 7 V Vas ascula a ar calc c cif f fica at atio io on n i is as ass soc ci ciat ated ed ed w w wit ith h h i in incr cre ea ease se s d d d ca ard rd rdio io iova va v sc scul ul ular ar r ri i isk k. k. I In n n a an nim ima al al mo mo mode de dels ls, , tr tr rea ea eatm tm tmen en ent t wi wi wit th v vit it tam am amin n n K K K an an nta ta tago go gon ni nist sts s s le le ed d d to to o a a arte e eria a al l calcification, n, , 38 38 38 a a and nd d l l lon on ng-g-g te e erm rm rm u use se se o of f f vi vita ta tami mi m n n n K K K an an nta ta tago go goni ni ist st s s s s wa wa was s s as a a so so oci ci ciat at ated ed ed w w wit it th h h ex ex extr tr trac ac a oronary to cluster after menopause. 41 Furthermore, women are likely to be exposed to risk factors for VTE earlier in life because of oral contraceptive use or pregnancy. A hypercoagulable state is found to play an important part in development of arterial events in younger subjects. 42 Thus, if arterial and venous thrombosis are caused by common risk factors other than atherosclerosis, a VTE may be more likely to occur before an arterial event in women and young men, whereas elderly men may be more prone to develop arterial events, irrespective of other risk factors, due to their high atherosclerotic burden. 40 The highest incidence rate of arterial thrombotic disease, MI and ischemic stroke was found the first year after a PE event. As the median duration of anticoagulant therapy after a PE was 12 months, many of the arterial thrombotic events occurred during anticoagulant treatment.
Oral anticoagulant treatment efficiently reduces the risk of MI and cerebrovascular events. 43, 44 Thus, it is likely to assume that the observed risk estimates are underestimations of the true risk of arterial events after a VTE in our study. This may also explain why our crude incidence rates of arterial thrombotic diseases after a VTE event were lower than those reported in previous cohort studies [4] [5] [6] [7] in which only VTE subjects who had completed oral anticoagulant treatment, 4 survived the first month after the VTE event, 7 or had no indication for long-term anticoagulant therapy 5, 7 were included. Moreover, the fact that we followed all VTE patients from the initial stage of the disease (including the 207 (17.1%) subjects who died within a year after the VTE episode and no longer were at risk of developing arterial thrombotic disease), and that all subjects with a history of cancer before enrolment (who are also at increased risk of arterial thrombotic events 45 ), were excluded from the DCH Study may additionally explain the lower incidence rate.
Our findings may have some clinical implications. Even though only 1% of the arterial was 12 months, many of the arterial thrombotic events occurred during anticoag gu ul ulan an nt tr tr trea a eatm tm tmen ent.
Oral anticoagulant treatment efficiently reduces the risk of MI and cerebrovascular events. 43, 44 Th hus us us, , , it it it i i is s s li li like ke k ly y t t to o o a assume that the observed risk k k es s stimates are und nd nderes es sti ti tim m mations of the true risk k k k of f a a ar rterial even ents ts s a a aft te er r r a VT VT VTE E E i in in o our ur ur s st tu ud d dy. T Th This m m ma ay y a al ls lso o o ex ex xp pl plai ain n n w wh why y ou u ur r c cr cru ud ude e in in inci ci c de de denc nc ce e ra r rat te es of f f a a art rt ter er eria ial l th th thr ro romb mb bo ot otic ic d di is sea ease e es s af af afte te ter r r a a VT VT VTE E E e ev even en ent t we we w re e e l low ow owe e er t t tha ha h n n n th th thos os o e e e r re repo po ort rt ted ed e i i in n n pr pre e evi io ious us s cohort studies es s thrombotic events in the total population could be attributed to incident venous thromboembolism, 64% of the arterial thrombotic events among the VTE patients were due to the incident VTE. Recent randomized controlled trials reported that acetylsalicylic acid (ASA) reduced the risk of recurrent VTE and major vascular events in patients with unprovoked VTE without increasing the risk of bleeding. 46, 47 ASA reduced the risk of major vascular events by 34% and recurrent VTE by 28%. 47 Extrapolated to our population, this may suggest prevention of 3 out of the 9 per 1000 major arterial events attributable to VTE in our population, and 50 out of the 180 per 1000 recurrent VTE events found in the randomized controlled trial.
The main strengths of our study include the prospective design, large number of participants recruited from a general population, wide age distribution, long-term follow-up, and validated events of VTE and arterial thrombotic disease. However, the study has some limitations. Non-response bias is a possible limitation of cohort studies as those who participate in cohort studies tend to be healthier than the general population. The risk estimates may therefore be lower than expected. Furthermore, due to a low number of both exposure and outcome events in our cohort, we may have lacked the statistical power to assess the potential impact of VTE on risk of arterial thrombotic disease in some subgroup-analyses.
In conclusion, our cohort study implies that all women and men below 65 years of age with incident VTE have increased risk of future arterial thrombotic disease, including myocardial infarction and ischemic stroke. However, only 1% of the arterial thrombotic events in the population can be attributed to VTE.
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